Roche Holding stock slips after Goldman Sachs lifts price target

Published on 09/15/2026 at 14:55 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Roche Holding stock trades lower on September 15, 2026 even as Goldman Sachs raises its price target to CHF 366 and keeps a Neutral rating. The shares follow a strong 5.0 percent gain to CHF 361.40 on September 14, 2026 on positive trial news.

Automatisches Diagnostik-Laborgerät mit Touchscreen-Oberfläche im klinischen Labor — Roche Holding AG CH0012032048 – Diagnostik-Analysegerät verarbeitet biologische Proben im modernen klinischen Labor, Illustration mit AI erstellt.

Roche Holding stock (ISIN CH0012032048) is trading softer on September 15, 2026, with the shares around CHF 358 on SIX Swiss Exchange after a strong 5.0 percent jump to CHF 361.40 at the close on September 14, 2026 as investors responded to positive Tam-Peli phase III trial results.

Goldman Sachs lifts target while staying Neutral

According to MarketScreener on September 15, 2026, Goldman Sachs analyst James Quigley reaffirmed a Neutral rating on Roche Holding and increased his 12-month price target from CHF 349 to CHF 366.

The Goldman Sachs move comes against an average analyst target price of about CHF 373.71 for Roche shares and a last closing price of CHF 361.40 on September 14, 2026, implying a potential upside of roughly 3.4 percent from that prior close according to the same MarketScreener overview.

Short-term price action after a 5.0 percent surge

At midday on September 15, 2026, Roche Holding stock was quoted around CHF 358.20 on SIX Swiss Exchange, down about 0.9 percent from the previous day’s CHF 361.40 close, based on delayed market data published by Investing.com.

This minor pullback follows a notable move the day before: as of the close on September 14, 2026, Roche Holding stock finished around CHF 361.40 on SIX Swiss Exchange, up 5.0 percent and outperforming the Swiss Market Index after investors reacted to positive Tam-Peli phase III trial results, as reported by Ad-hoc News.

Analyst earnings expectations frame the risk

Beyond price targets, analysts are also focused on Roche’s earnings trajectory. Experts cited by finanzen.ch on September 15, 2026 estimate that Roche could report earnings of CHF 20.41 per share for fiscal year 2026, a figure that will be measured against results delivered in the most recent quarters once they are published.

The combination of a raised Goldman Sachs price target to CHF 366, a modest upside versus the consensus average target of roughly CHF 373.71, and an earnings expectation of CHF 20.41 per share for 2026 highlights a balanced risk-reward profile: analysts see upside from current levels, but they also point to earnings execution as a key factor for Roche Holding stock.

Stock level and investor takeaway

As of September 15, 2026, around 12:30 p.m. local time, Roche Holding stock is trading near CHF 358 on SIX Swiss Exchange, modestly below the prior CHF 361.40 close and a few percent under the average analyst target of approximately CHF 373.71, leaving some room for potential appreciation if the company meets or exceeds earnings expectations.